Metraipolis › archive › dc_4d11beb2ab01
Lenvatinib potentiates the antitumor efficacy of combined radiotherapy and PD-L1 blockade in lung adenocarcinoma — Europe PMC PMID:41481002
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41481002
- DOI
- 10.1080/15384047.2025.2610526
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T03:12:15.378Z
- SHA-256 of the archived text
c79b0ea73acc6fc5fde7f64966fe72998abc3ef5adbcfe525657ddf5786c0ca2- Stable URL of this page
https://metraipolis.com/documento/dc_4d11beb2ab01
How to cite
Lenvatinib potentiates the antitumor efficacy of combined radiotherapy and PD-L1 blockade in lung adenocarcinoma — Europe PMC PMID:41481002 — Europe PMC (en), https://europepmc.org/article/MED/41481002 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4d11beb2ab01 (Metraipolis archive dc_4d11beb2ab01, sha256 c79b0ea73acc6fc5fde7f64966fe72998abc3ef5adbcfe525657ddf5786c0ca2)
BibTeX
@misc{dc4d11beb2ab01,
title = {Lenvatinib potentiates the antitumor efficacy of combined radiotherapy and PD-L1 blockade in lung adenocarcinoma — Europe PMC PMID:41481002},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41481002},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4d11beb2ab01; sha256 c79b0ea73acc6fc5fde7f64966fe72998abc3ef5adbcfe525657ddf5786c0ca2},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41481002. Agents can read the archived copy with the MCP tool read_document.